TCB008 in Patients With COVID-19

Status:
Not yet recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

A Phase II safety and tolerability study of expanded gamma delta T cell lymphocytes (TCB008) in patients diagnosed with COVID-19.

Phase 2

TC Biopharm